Advertisement

Tumor Biology

, Volume 37, Issue 2, pp 2153–2159 | Cite as

The clinical and biological significance of MICA in clear cell renal cell carcinoma patients

  • Xiang Zhang
  • Lei Yan
  • Wei Jiao
  • Juchao Ren
  • Naidong Xing
  • Yongzhen Zhang
  • Yuanwei Zang
  • Jue Wang
  • Zhonghua Xu
Original Article

Abstract

Major histocompatibility complex class I-related chains A (MICA), a ligand of Natural killer group 2, member D (NKG2D) receptor, is broadly upregulated in epithelial originated tumor cells. MICA plays a critical role in the immune surveillance against tumor cells and is associated with the prognosis of several malignancies. The aim of this study is to evaluate the clinical and biological significance of MICA in clear cell renal cell carcinoma (ccRCC). The expression of MICA was analyzed by quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC). Both MICA mRNA and protein levels were upregulated in ccRCC tissues, compared with normal tissues. IHC staining revealed a homogenous pattern of MICA staining within each tumor, which combined both membrane staining and granular cytoplasmic staining. Furthermore, high MICA expression was associated with lymph node metastasis and advanced clinical stage and predicted poor prognosis in patients with ccRCC. Gene set enrichment analysis (GSEA) was performed using RNA-sequencing data from The Cancer Genome Atlas Research Network (TCGA) to elucidate the biological role of MICA in ccRCC and revealed that MICA was significantly associated with the epithelial-to-mesenchymal transition (EMT) gene set, which was further confirmed by qRT-PCR. Our findings contribute to the studies on biomarkers of kidney cancers and the mechanism of renal cancer progression driven by EMT pathway.

Keywords

MICA Renal cell carcinoma Prognosis EMT NKG2D 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (no. 81372335) and China Postdoctoral Science Foundation (no. 2014M551915).

Conflicts of interest

None

References

  1. 1.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMedGoogle Scholar
  2. 2.
    Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin N Am. 2003;30:843–52.CrossRefGoogle Scholar
  3. 3.
    Eisengart LJ, MacVicar GR, Yang XJ. Predictors of response to targeted therapy in renal cell carcinoma. Arch Pathol Lab Med. 2012;136:490–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced mhc molecules by intestinal epithelial gammadelta t cells. Science. 1998;279:1737–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of nk cells and t cells by nkg2d, a receptor for stress-inducible mica. Science. 1999;285:727–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, et al. Functional expression and release of ligands for the activating immunoreceptor nkg2d in leukemia. Blood. 2003;102:1389–96.CrossRefPubMedGoogle Scholar
  7. 7.
    Watson NF, Spendlove I, Madjd Z, McGilvray R, Green AR, Ellis IO, et al. Expression of the stress-related mhc class i chain-related protein mica is an indicator of good prognosis in colorectal cancer patients. Int J Cancer J Int Cancer. 2006;118:1445–52.CrossRefGoogle Scholar
  8. 8.
    Chen Y, Lin G, Guo ZQ, Zhou ZF, He ZY, Ye YB. Effects of mica expression on the prognosis of advanced non-small cell lung cancer and the efficacy of cik therapy. PLoS ONE. 2013;8:e69044.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wu J, Zhang XJ, Shi KQ, Chen YP, Ren YF, Song YJ, et al. Hepatitis b surface antigen inhibits mica and micb expression via induction of cellular mirnas in hepatocellular carcinoma cells. Carcinogenesis. 2014;35:155–63.CrossRefPubMedGoogle Scholar
  10. 10.
    Li JJ, Pan K, Gu MF, Chen MS, Zhao JJ, Wang H, et al. Prognostic value of soluble mica levels in the serum of patients with advanced hepatocellular carcinoma. Chin J Cancer. 2013;32:141–8.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kumar V, Yi Lo PH, Sawai H, Kato N, Takahashi A, Deng Z, et al. Soluble mica and a mica variation as possible prognostic biomarkers for hbv-induced hepatocellular carcinoma. PLoS ONE. 2012;7:e44743.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zhang J, Xu Z, Zhou X, Zhang H, Yang N, Wu Y, et al. Loss of expression of mhc class i-related chain a (mica) is a frequent event and predicts poor survival in patients with hepatocellular carcinoma. Int J Clin Exp Pathol. 2014;7:3123–31.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NF, et al. Upregulation of mica on high-grade invasive operable breast carcinoma. Cancer Immun. 2007;7:17.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Tamaki S, Sanefuzi N, Kawakami M, Aoki K, Imai Y, Yamanaka Y, et al. Association between soluble mica levels and disease stage iv oral squamous cell carcinoma in japanese patients. Hum Immunol. 2008;69:88–93.CrossRefPubMedGoogle Scholar
  15. 15.
    Eble J, Sauter G, Epstein J, Sesterhenn IE. World health organization classification of tumors pathology and genetics of the urinary systemandmale genital organs. Lyon: LARC Press; 2004. p. 12–4.Google Scholar
  16. 16.
    Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655–63.CrossRefPubMedGoogle Scholar
  17. 17.
    Lee J, Jeong S, Lee CR, Ku CR, Kang SW, Jeong JJ, et al. Gli1 transcription factor affects tumor aggressiveness in patients with papillary thyroid cancers. Medicine. 2015;94:e998.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Lopez-Soto A, Huergo-Zapico L, Galvan JA, Rodrigo L, de Herreros AG, Astudillo A, et al. Epithelial-mesenchymal transition induces an antitumor immune response mediated by nkg2d receptor. J Immunol. 2013;190:4408–19.CrossRefPubMedGoogle Scholar
  19. 19.
    Jia HY, Liu JL, Zhou CJ, Kong F, Yuan MZ, Sun WD, et al. High expression of mica in human kidney cancer tissue and renal cell carcinoma lines. Asian Pac J Cancer Prev : APJCP. 2014;15:1715–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Roberts AI, Lee L, Schwarz E, Groh V, Spies T, Ebert EC, et al. Nkg2d receptors induced by il-15 costimulate cd28-negative effector ctl in the tissue microenvironment. J Immunol. 2001;167:5527–30.CrossRefPubMedGoogle Scholar
  21. 21.
    Xiao P, Xue L, Che LH, Peng JJ, Wu HX, Li Y, et al. Expression and roles of mica in human osteosarcoma. Histopathology. 2008;52:640–2.CrossRefPubMedGoogle Scholar
  22. 22.
    Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, et al. Clinical significance of the nkg2d ligands, mica/b and ulbp2 in ovarian cancer: High expression of ulbp2 is an indicator of poor prognosis. Cancer Immunol Immunother. 2009;58:641–52.CrossRefPubMedGoogle Scholar
  23. 23.
    Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble mic ligands impair expression of nkg2d and t-cell activation. Nature. 2002;419:734–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Salih HR, Rammensee HG, Steinle A. Cutting edge: Down-regulation of mica on human tumors by proteolytic shedding. J Immunol. 2002;169:4098–102.CrossRefPubMedGoogle Scholar
  25. 25.
    Sconocchia G, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W, et al. Defective infiltration of natural killer cells in mica/b-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction. Neoplasia. 2009;11:662–71.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC. Melanoma cells inhibit nk cell functions. Cancer Res. 2012;72:5428–9. author reply 5430.CrossRefPubMedGoogle Scholar
  27. 27.
    Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, et al. Bcr/abl oncogene directly controls mhc class i chain-related molecule a expression in chronic myelogenous leukemia. J Immunol. 2006;176:5108–16.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Xiang Zhang
    • 1
  • Lei Yan
    • 1
  • Wei Jiao
    • 1
  • Juchao Ren
    • 1
  • Naidong Xing
    • 1
  • Yongzhen Zhang
    • 1
  • Yuanwei Zang
    • 1
  • Jue Wang
    • 2
  • Zhonghua Xu
    • 1
  1. 1.Department of Urology, Qilu HospitalShandong UniversityJinanChina
  2. 2.Central LaboratoryThe Second Hospital of Shandong UniversityJinanChina

Personalised recommendations